Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has published a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform identified a four-gene prognostic signature in hepatocellular carcinoma (HCC), a form of liver cancer. The study, published Oct. 23, 2026, used Partitioned Literature Aggregation (PLA), Oncotelic's patented algorithm running on PDAOAI, along with gene-expression and survival analyses to pinpoint four genes: FKBP1A, EIF4E, RRAGC and PPARGC1A. The signature's association with patient survival was independently validated in a Japanese HCC cohort of 203 patients.
The findings matter because they support patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus. By identifying patients more likely to respond based on their genetic profile, Oncotelic could improve the odds of success in later-stage testing—a critical step for a company developing therapies for cancers with substantial unmet needs. Oncotelic Chief Business Officer Saran Saund presented the research approach during an Oct. 22 keynote at the 22nd Drug Discovery Strategic Summit in California, highlighting the potential of partitioned AI investigations to uncover testable biological hypotheses and advance drug discovery.
The publication also signals broader ambitions for PDAOAI. Oncotelic plans to expand the platform toward a target scale of approximately 100 billion biological vectors for genetic and protein research. Through its BIO REBOOT initiative, the company invites researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning and clinical development, subject to scientific review and available resources. This collaborative model could accelerate the translation of AI-derived insights into tangible therapies.
For investors, the peer-reviewed validation of PDAOAI's utility is a key milestone. It lends credibility to the company's AI-driven approach at a time when computational drug discovery is attracting intense interest. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. To view the full press release, visit https://ibn.fm/ctJ4J.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions. For full terms of use and disclaimers, see https://www.BioMedWire.com/Disclaimer.
